Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact

Isin GB0009895292
Ticker AZN
Currency $
Aware Investor Index (AII) 143.0185
Recommendation STRONG BUY
P/E 6.94
ROE 29.16 %
Capitalization 37,444,000,000 $
Dividend Yield 9.46 %
P/S 1.58
AII Position 28
P/E Position 20
ROE Position 102
Capitalization Position 226
Dividend Yield Position 8
Sales 23,641,000,000 $
10-Year Average Earnings 5,396,600,000 $
Shares Outstanding 1,265,000,000
Equity 18,509,000,000 $
Dividend per Share 2.8 $
Industry Pharmaceutical
Country Great Britain
ASTRAZENECA Investor Relations Web Site http://www.astrazeneca.com/Investors


2015 12 23,641,000,000.00 $
2014 12 26,095,000,000.00 $
2013 12 25,711,000,000.00 $
2012 12 27,973,000,000.00 $
2011 12 33,591,000,000.00 $
2010 12 33,269,000,000.00 $
2009 12 32,804,000,000.00 $
2008 12 31,601,000,000.00 $
2007 12 29,559,000,000.00 $
2006 12 26,475,000,000.00 $


2015 12 2,488,000,000.00 $
2014 12 -271,000,000.00 $
2013 12 2,458,000,000.00 $
2012 12 6,405,000,000.00 $
2011 12 9,470,000,000.00 $
2010 12 8,106,000,000.00 $
2009 12 7,490,000,000.00 $
2008 12 6,130,000,000.00 $
2007 12 5,627,000,000.00 $
2006 12 6,063,000,000.00 $


2015 12 18,509,000,000.00 $
2014 12 19,646,000,000.00 $
2013 12 23,253,000,000.00 $
2012 12 23,952,000,000.00 $
2011 12 23,472,000,000.00 $
2010 12 23,410,000,000.00 $
2009 12 20,821,000,000.00 $
2008 12 16,060,000,000.00 $
2007 12 14,915,000,000.00 $
2006 12 15,416,000,000.00 $

Shares Outstanding:

2015 12 1,265,000,000
2014 12 1,264,000,000
2013 12 1,254,000,000
2012 12 1,261,000,000
2011 12 1,367,000,000
2010 12 1,446,000,000
2009 12 1,450,000,000
2008 12 1,453,000,000
2007 12 1,495,000,000
2006 12 1,564,000,000


Bloomberg News for ASTRAZENECA:

Mar 21, 2018
Russia Spy Poisoning: Interpol Is Also a Crime Victim
on diffusions aren't published, but that total is probably even higher. Azerbaijan, China, Russia, Turkey and Venezuela -- none of them model states for the rule of law -- have led the charge.The...
Feb 15, 2018
For Olympic Glory, Athletes Need Talent and a Billionaire Backer
Frederick Snyder (red) of the United States wrestles against Khetag Goziumov (blue) of Azerbaijan during the Men’s Freestyle 97kg Gold medal match at the Rio 2016 Olympic Games.Photographer: Laurence...
Feb 19, 2018
Gallery of ECB Governors in Legal Woe Grows on Latvia Case
of the central bank’s money-printing unit had paid bribes to win contracts from the Azeri and Syrian national banks. While the managers were found guilty, the court didn’t find evidence that Duchatczek...
Feb 5, 2018
Azeri Leader Aliyev Calls Snap Presidential Election for April
the decision on Monday. The election was previously slated for Oct. 17. The ruling New Azerbaijan Party, known as YAP, earlier said it would nominate Aliyev for the presidency again, potentially...
Jan 30, 2018
Europe's Natural Gas Market Is Heading South
developing with BP Plc and the State Oil Co. of Azerbaijan. That link will bring gas from the Caspian Sea, opening what EU authorities hope will become an new southern corridor for supplies. It will help...
Jan 26, 2018
In Defense of Good Old Per Capita GDP
while Slovakia is an advanced one). One could also argue with some of the results. Azerbaijan's IDI is higher than that of the U.S., Japan, Spain or Italy. That should warm the heart of its dictator...
Jan 9, 2018
Greece Reaps Benefits From This Underground Pipe
desperately trying to attract foreign direct investment, a pipeline bringing gas from Azerbaijan to Europe shows just what a difference such deals can make.Basic metals production has been the star...
Jan 7, 2018
Don't Expect OPEC's Oil Output Deal to Collapse in 2018
for output reductions of more than 20,000 barrels a day came from Oman, Mexico and Azerbaijan. Of those three, Oman has a history of working with the producer group when times are particularly...
Jan 11, 2018
Why Russians Are Choosing Malta Over Putin
now, includes a Saudi sheikh arrested in the recent purge, Pakistani tycoons and an Azerbaijani banker. Also, dozens of Russians.The best known and likely the wealthiest of them is Arkady Volozh...
Dec 6, 2017
Goldman Alum to Help Sell Debt From Places Few Investors Know
to pinpoint on an atlas.With a new hire from Goldman Sachs Group Inc. co-heading its Russian corporate and investment-banking unit, Raiffeisen is positioning for new deals in the former Soviet Union...

Google News for ASTRAZENECA:

Macon Daily - 23 hours ago
AstraZeneca (AZN) Upgraded to Buy at Jefferies Group
AstraZeneca plc logo Jefferies Group upgraded shares of AstraZeneca (LON:AZN) from a hold rating to a buy rating in a research note released on Monday. Jefferies Group currently has GBX 5,600 ($77.37) price objective on the biopharmaceutical company's stock, up from their previous price objective of ...
Jefferies Upgrades AstraZeneca (AZN) to Buy
Jefferies upgraded AstraZeneca (NYSE: AZN) from Hold to Buy. Analyst Ian Hilliker comments "AstraZeneca is at a turning point. Accelerating new product launches and improving margins should deliver over 20% CORE EPS growth in the mid term. As one-off externalisation contributions decline CORE ...
Newburgh Gazette
AstraZeneca (AZN) Presents New Data Evaluating Safety, Efficacy of ...
AstraZeneca (NYSE: AZN) today announced the results of DERIVE, a Phase 3 study that evaluated the efficacy and safety of FARXIGA® (dapagliflozin 10 mg), in patients with type 2 diabetes (T2D) with moderate renal impairment (chronic kidney disease [CKD] stage 3A with eGFR of 45-59 mL /min /1 ...
Frisco Fastball
Why A Biopharma Buying Spree May Target AstraZeneca, Bristol
AstraZeneca (AZN), Bristol-Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX) are the likeliest targets of a biopharma "detonation event" in which tax reform spurs ... Celgene, Biogen and AstraZeneca would be most accretive to a potential acquirer, based on short-term financials, Fernandez said.
StreetInsider.com - 1 day ago
AstraZeneca Breaks Above 200-Day Moving Average - Bullish for AZN
In trading on Monday, shares of AstraZeneca plc (Symbol: AZN) crossed above their 200 day moving average of $33.39, changing hands as high as $33.63 per share. AstraZeneca plc shares are currently trading up about 1.4% on the day. The chart below shows the one year performance of AZN shares, ...
Simply Wall St
AstraZeneca spins out 6 drugs and an R&D group into Viela Bio ...
AstraZeneca $AZN has culled its pipeline of preclinical through mid-stage anti-inflammatory/autoimmune drugs at its big MedImmune subsidiary in Gaithersburg, MD and spun out six programs into a new startup called Viela Bio. Viela springs into existence today with the support of a group of three marquee ...
AstraZeneca (AZN) Reports Renewed Recommendation, Availability ...
AstraZeneca (NYSE: AZN) today announced that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has voted in favor of a renewed recommendation for the use of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) in the US ...
Proactive Investors UK
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
AstraZeneca AZN announced that the FDA has approved a second indication for its PD-L1 inhibitor, Imfinzi. It is now approved for unresectable Stage III non-small cell lung cancer ("NSCLC"). The drug is meant for patients whose disease has not progressed following concurrent platinum-based ...
StreetInsider.com - 1 day ago
BMO Capital Reiterates Outperform on AstraZeneca (AZN ...
BMO Capital reiterated an Outperform rating and $40.00 price target on AstraZeneca (NYSE: AZN) following the company's announced FDA approval of Imfinzi in Stage III unresectable NSCLC. Analyst Alex Arfaei believes that there is a reasonable chance that Imfinzi in Stage III NSCLC could reach ...
Seeking Alpha
What's AstraZeneca's Valuation in March 2018?
As of March 9, 2018, AstraZeneca (AZN) was trading at a forward PE multiple of ~19.3x as compared to the industry average of 12.9x. Some competitors like Eli Lilly (LLY), Merck (MRK), and Pfizer (PFE) are trading at a lower forward PE multiple of 15.8x, 13.0x, and 12.3x, respectively, as compared to AstraZeneca.